Immuneering (IMRX) Enterprise Value (2020 - 2026)

Immuneering's Enterprise Value history runs 7 years deep, the most recent figure standing at -$156.7 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 336.89% year-over-year to -$156.7 million in Q1 2026; TTM through Mar 2026 was -$156.7 million, a 336.89% decrease from a year earlier, with the FY2025 full-year figure at -$172.8 million, down 378.16% from the prior year.
• Enterprise Value advanced to -$156.7 million in Q1 2026 per IMRX's latest filing, from -$172.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$26.4 million in Q2 2025 and bottomed at -$227.6 million in Q3 2025.
• The 5-year median for Enterprise Value is -$97.2 million (2023), against an average of -$100.5 million.
• Across the five-year window, Enterprise Value surged 57.81% in 2024 and tumbled 378.16% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$105.5 million in 2022, then gained by 18.82% to -$85.7 million in 2023, then jumped by 57.81% to -$36.1 million in 2024, then tumbled by 378.16% to -$172.8 million in 2025, then rose by 9.34% to -$156.7 million in 2026.
• Per Business Quant, the three latest IMRX Enterprise Value figures stand at -$156.7 million (Q1 2026), -$172.8 million (Q4 2025), and -$227.6 million (Q3 2025).